How much funding has FogPharma raised?

FogPharma has raised $694.0M in total funding, most recently a Series F round.

Who are FogPharma's investors?

FogPharma's investors include RA Capital Management, ARCH Venture Partners, Nextech Invest, 6 Dimensions Capital, venBIO Partners, Cormorant Asset Management.

Where is FogPharma headquartered?

FogPharma is headquartered in Cambridge, Massachusetts, United States.

What industry is FogPharma in?

FogPharma operates in Biotech, Drug Discovery.

How many employees does FogPharma have?

FogPharma has 51-200 employees.

FogPharma

Creating extraordinary medicines.

Cambridge, United States · Founded 2016 · $694.0M raised

Biotech

Drug Discovery

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2016
Business Model: B2B

Website: fogpharma.com
Total Funding: $694.0M
Last Round: $305.0M Series FJan 2025
Rounds: 4

About

FogPharma (rebranded as Parabilis Medicines in October 2024) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company pioneered a new class of alpha-helical peptides called Helicons™, capable of modulating intracellular proteins historically beyond the reach of conventional medicines. Its lead program, FOG-001 (zolucatetide), is the first and only direct inhibitor of the beta-catenin transcriptional co-activator complex and is in active clinical development across multiple tumor types including adamantinomatous craniopharyngioma. In January 2026, Parabilis raised an oversubscribed $305 million financing to advance FOG-001 and its broader Helicon platform.

Summary

FogPharma is a Biotech company based in Cambridge, United States, founded in 2016. It has raised $694.0M in total across 4 rounds, most recently a $305.0M Series F round in Jan 2025. Investors include RA Capital Management, ARCH Venture Partners and Nextech Invest.